There is a flourishing biosimilar industry in Latin America, with its own research, development, production and commercialization capacity
It’s important to consider how product drift will impact biosimilars
FDA looks to improve transparency and predictability for generic drug applicants
Reaching new frontiers will require both strategic and financial planning
White Papers: In Depth Research
Posted: Feb 08, 2017
As pharma companies look more and more to biologics for their next potential blockbusters, they must face the challenges surrounding these products' scientific complexity and sophisticated development.